Proceedings from the American College of Rheumatology Reproductive Health Summit: The management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases

Arthritis Care and Research

Volumn 67, Issue 3, 2015, Pages 313-325

  Kavanaugh, Arthur ^a   Cush, John J ^b   Ahmed, Mahmoud S ^c   Bermas, Bonnie L ^d   Chakravarty, Eliza ^e   Chambers, Christina ^a   Clowse, Megan ^f   Curtis, Jeffrey R ^g   Dao, Kathryn ^b   Hankins, Gary D V ^c   Koren, Gideon ^h   Kim, Seoyoung C ^d   Lapteva, Larissa ⁱ   Mahadevan, Uma ^j   Moore, Thomas ^k   Nolan, Martha ^l   Ren, Zhaoxia ^m   Sammaritano, Lisa R ⁿ   Seymour, Sally ⁱ   Weisman, Michael H ^o  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l Society for Women's Health Research   (United States)

^m EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁿ WEILL CORNELL MEDICAL COLLEGE   (United States)

^o CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIASTHMATIC AGENT; ANTIVIRUS AGENT; APREMILAST; AZATHIOPRINE; BCG VACCINE; DIPHTHERIA VACCINE; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; INFLUENZA VACCINE; LEFLUNOMIDE; MENINGITIS VACCINE; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PERTUSSIS VACCINE; STEROID; TERIFLUNOMIDE; TETANUS TOXOID; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; USTEKINUMAB; IMMUNOLOGIC FACTOR;

ARTICLE; AUTOIMMUNE DISEASE; DRUG LABELING; DRUG RESEARCH; DRUG TRANSPORT; FEMALE FERTILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATION; LACTATION; LEGAL ASPECT; MEDICAL SCHOOL; PLACENTA FUNCTION; PREGNANCY; RESEARCH ETHICS; ANIMAL; AUTOIMMUNE DISEASES; COMPLICATION; DRUG EFFECTS; FEMALE; FERTILITY; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PATIENT SAFETY; PERINATAL CARE; PREGNANCY COMPLICATIONS; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; AUTOIMMUNE DISEASES; BIOMEDICAL RESEARCH; FEMALE; FERTILITY; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; LACTATION; PATIENT SAFETY; PERINATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS;

EID: 84923303586     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22516     Document Type: Article

References (107)

1. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011;84:478-85.
2. Ventura SJ, Curtin SC, Abma JC, Henshaw SK. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008. Hyattsville, MD: National Center for Health Statistics; 2012. p. 60.
3. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205:51.e1-8.
4. USA Food and Drug Administration. Pregnancy: a time for special caution. 2013. URL: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM351522.pdf.
5. Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989;160:1190-4.
6. Koren G, Pastuszak A. Prevention of unnecessary pregnancy terminations by counselling women on drug, chemical, and radiation exposure during the first trimester. Teratology 1990;41:657-61.
7. Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998;42:1336-9.
8. Cohen-Kerem R, Nulman I, Abramow-Newerly M, Medina D, Maze R, Brent RL, et al. Diagnostic radiation in pregnancy: perception versus true risks. J Obstet Gynaecol Can 2006;28:43-8.
9. US Food and Drug Administration. Reviewer guidance: evaluating the risks of drug exposure in human pregnancies. 2005. URL: http://www.fda.gov/downloads/scienceresearch/specialtopics/womenshealthresearch/ucm133359.pdf.
10. Bird TM, Hobbs CA, Cleves MA, Tilford JM, Robbins JM. National rates of birth defects among hospitalized newborns. Birth Defects Res Clin Mol Teratol 2006;76:762-9.
11. US Department of Health and Human Services. Code of Federal Regulations, Title 45 Part 46. URL: http://www.hhs.gov/ohrp/archive/humansubjects/guidance/45cfr46.html.
12. US Food and Drug Administration. Guidance for industry: establishing pregnancy exposure registries. 2002. URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071639.pdf.
13. Olesen C, Sondergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, Olsen J, et al. Do pregnant women report use of dispensed medications? Epidemiology 2001;12:497-501.
14. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL, BSRBR Control Centre Consortium. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:823-6.
15. Cush JJ, Reed G, Saunders KC, Kremer JM, Greenberg JD, Kavanaugh A. DMARD and biologic use during pregnancy among rheumatoid and psoriatic arthritis patients in the Corrona Registry [abstract]. Arthritis Rheum 2012;64 Suppl 10:S166.
16. Kuriya B, Hernandez-Diaz S, Liu J, Bermas BL, Daniel G, Solomon DH. Patterns of medication use during pregnancy in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:721-8.
17. USA Food and Drug Administration. Mini-sentinel. 2014. URL: http://www.mini-sentinel.org/.
18. Flood J. President's perspective: the ACR's RISE registry will simplify reporting, comparing clinical data. 2014. URL: http://www.the-rheumatologist.org/details/article/5713321/Presidents-Perspective-The-ACRs-RISE-Registry-Will-Simplify-Reporting-Comparing-.html.
19. Rosati K, Evans B, McGraw D. Health Insurance Portability and Accountability Act (HIPAA) and Common Rule Compliance in the Mini-Sentinel Pilot. URL: http://mini-sentinel.org/work-products/About-Us/HIPAA-and-CommonRuleCompliance-in-the-Mini-SentinelPilot.pdf.
20. Rytting E, Ahmed MS. Fetal drug therapy. In: Mattison D, editor. Clinical pharmacology during pregnancy. San Diego: Elsevier; 2013. p. 55-66.
21. Nanovskaya TN, Hankins GD, Ahmed MS. The placenta as a functional barrier to fetal drug exposure. In: Kay H, Nelson DM, Wang Y, editors. The placenta from development to disease. Chichester: Wiley-Blackwell; 2011. p. 303-9.
22. th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2010.
23. Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance Program. Arthritis Rheum 2014;66:369-78.
24. US Department of Health and Human Services National Institute of Child Health and Human Development. What are the factors that put a pregnancy at risk? 2013. URL: http://www.nichd.nih.gov/health/topics/high-risk/conditioninfo/Pages/factors.aspx.
25. Da Silva JA, Spector TD. The role of pregnancy in the course and aetiology of rheumatoid arthritis. Clin Rheumatol 1992;11:189-94.
26. Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med 1993;329:466-71.
27. Yan Z, Lambert NC, Ostensen M, Adams KM, Guthrie KA, Nelson JL. Prospective study of fetal DNA in serum and disease activity during pregnancy in women with inflammatory arthritis. Arthritis Rheum 2006;54:2069-73.
28. De Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008;59:1241-8.
29. Brouwer J, Hazes JM, Laven JS, Dolhain RJ. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis 2014. E-pub ahead of print.
30. Clowse ME, Chakravarty E, Costenbader KH, Chambers C, Michaud K. Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012;64:668-74.
31. Provost M, Eaton JL, Clowse ME. Fertility and infertility in rheumatoid arthritis. Curr Opin Rheumatol 2014;26:308-14.
32. De Man YA, Dolhain RJ, Hazes JM. Disease activity or remission of rheumatoid arthritis before, during and following pregnancy. Curr Opin Rheumatol 2014;26:329-33.
33. Wallenius M, Salvesen KA, Daltveit AK, Skomsvoll JF. Rheumatoid arthritis and outcomes in first and subsequent births based on data from a national birth registry. Acta Obstet Gynecol Scand 2014;93:302-7.
34. Chaudhary P, Clowse ME. Prednisone use associated with worse outcomes in rheumatoid arthritis pregnancies [abstract]. Arthritis Rheum 2013;65 Suppl 10:S562.
35. Vinet E, Labrecque J, Pineau CA, Clarke AE, St-Pierre Y, Platt R, et al. A population-based assessment of live births in women with systemic lupus erythematosus. Ann Rheum Dis 2012;71:557-9.
36. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:899-907.
37. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008;199:127 e1-6.
38. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001;10:401-4.
39. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007;133:1106-12.
40. Norgard B, Hundborg HH, Jacobsen BA, Nielsen GL, Fonager K. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007;102:1947-54.
41. Khashu M, Narayanan M, Bhargava S, Osiovich H. Perinatal outcomes associated with preterm birth at 33 to 36 weeks' gestation: a population-based cohort study. Pediatrics 2009;123:109-13.
42. Kitsommart R, Janes M, Mahajan V, Rahman A, Seidlitz W, Wilson J, et al. Outcomes of late-preterm infants: a retrospective, single-center, Canadian study. Clin Pediatr (Phila) 2009;48:844-50.
43. Lindstrom K, Winbladh B, Haglund B, Hjern A. Preterm infants as young adults: a Swedish national cohort study. Pediatrics 2007;120:70-7.
44. McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births compared with births at term. Obstet Gynecol 2008;111:35-41.
45. Ment LR, Kesler S, Vohr B, Katz KH, Baumgartner H, Schneider KC, et al. Longitudinal brain volume changes in preterm and term control subjects during late childhood and adolescence. Pediatrics 2009;123:503-11.
46. Morse SB, Zheng H, Tang Y, Roth J. Early school-age outcomes of late preterm infants. Pediatrics 2009;123:e622-9.
47. Mahadevan U, Martin CF, Chambers C, Kane SV, Dubinsky M, Sandborn W, et al. Achievement of developmental milestones among offspring of women with inflammatory bowel disease: the PIANO Registry. Gastroenterology 2014;146:S-1.
48. Lin K, Martin CF, Dassopoulos T, Esposti SD, Wolf DC, Esposti SD, et al. 2 pregnancy outcomes amongst mothers with inflammatory bowel disease exposed to systemic corticosteroids: results of the PIANO Registry. Gastroenterology 2014;146:S-1.
49. Marder W, Fisseha S, Ganser MA, Somers EC. Ovarian damage during chemotherapy in autoimmune diseases: broad health implications beyond fertility. Clin Med Insights Reprod Health 2012;2012:9-18.
50. Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, et al. Study of anti-Mullerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab 2013;98:3785-92.
51. Klieger-Grossmann C, Chitayat D, Lavign S, Kao K, Garcia-BournissenF, Quinn D, et al. Prenatal exposure to mycophenolate mofetil: an updated estimate. J Obstet Gynaecol Can 2010;32:794-7.
52. Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 2012;158A:588-96.
53. Lipscomb GH. Medical therapy for ectopic pregnancy. Semin Reprod Med 2007;25:93-8.
54. Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503.
55. Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, on behalf of the Network of French Pharmacovigilance Centers, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheum 2014;66:1101-10.
56. Elliott AB, Chakravarty EF. Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Womens Health (Lond Engl) 2010;6:431-40.
57. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961-8.
58. Hutson JR, Matlow JN, Moretti ME, Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol 2013;33:1-8.
59. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001;71:1051-5.
60. Marder W, Ganser MA, Romero V, Hyzy MA, Gordon C, McCune WJ, et al. In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013;65:759-66.
61. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385-92.
62. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992;166:1318-23.
63. Chakravarty EF, Colon I, Langen ES, Nix DA, El-Sayed YY, Genovese MC, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005;192:1897-904.
64. Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci 2014;1317:32-8.
65. Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 2009;61:587-92.
66. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92.
67. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012;2012:985646.
68. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996;36:248-55.
69. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010;4:603-5.
70. Mahadevan U, Martin CF, Dubinsky M, Kane SV, Sands BE, Sandborn W. Exposure to anti-TNFα therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO Registry. Gastroenterology 2014;146:S-170.
71. Prescott GM, Matthews CM. Long-acting reversible contraception: a review in special populations. Pharmacotherapy 2014;34:46-59.
72. Chakravarty EF. What we talk about when we talk about contraception. Arthritis Rheum 2008;59:760-1.
73. Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002;187:1623-30.
74. Townsend RJ, Benedetti TJ, Erickson SH, Cengiz C, Gillespie WR, Gschwend J, et al. Excretion of ibuprofen into breast milk. Am J Obstet Gynecol 1984;149:184-6.
75. Katz FH, Duncan BR. Entry of prednisone into human milk [letter]. N Engl J Med 1975;293:1154.
76. Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ Jr. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993;53:324-8.
77. Cimaz R, Brucato A, Meregalli E, Muscara M, Sergi P. Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al [letter]. Arthritis Rheum 2004;50:3056-7; author reply 7-8.
78. Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005;25:86-9.
79. Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 1987;76:137-42.
80. Jarnerot G, Into-Malmberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol 1979;14:869-71.
81. Branski D, Kerem E, Gross-Kieselstein E, Hurvitz H, Litt R, Abrahamov A. Bloody diarrhea: a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr 1986;5:316-7.
82. Orme ML, Lewis PJ, de Swiet M, Serlin MJ, Sibeon R, Baty JD, et al. May mothers given warfarin breast-feed their infants?Br Med J 1977;1:1564-5.
83. Palmeira P, Costa-Carvalho BT, Arslanian C, Pontes GN, Nagao AT, Carneiro-Sampaio MM. Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin. Pediatr Allergy Immunol 2009;20:528-35.
84. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk [letter]. Am J Obstet Gynecol 1972;112:978-80.
85. Wiernik PH, Duncan JH. Cyclophosphamide in human milk. Lancet 1971;1:912.
86. Durodola JI. Administration of cyclophosphamide during late pregnancy and early lactation: a case report. J Natl Med Assoc 1979;71:165-6.
87. Amato D, Niblett JS. Neutropenia from cyclophosphamide in breast milk. Med J Aust 1977;1:383-4.
88. Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Barclay ML, Begg EJ. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006;62:453-6.
89. Moretti ME, Verjee Z, Ito S, Koren G. Breast-feeding during maternal use of azathioprine. Ann Pharmacother 2006;40:2269-72.
90. Angelberger S, Reinisch W, Messerschmidt A, Miehsler W, Novacek G, Vogelsang H, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis 2011;5:95-100.
91. Munoz-Flores-Thiagarajan KD, Easterling T, Davis C, Bond EF. Breast-feeding by a cyclosporine-treated mother. Obstet Gynecol 2001;97:816-8.
92. Nyberg G, Haljamae U, Frisenette-Fich C, Wennergren M, Kjellmer I. Breast-feeding during treatment with cyclosporine. Transplantation 1998;65:253-5.
93. Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, et al. Cyclosporine excretion into breast milk. Transplantation 2003;75:2144-6.
94. Armenti VT, Radomski JS, Moritz MJ, Gaughan WJ, Hecker WP, Lavelanet A, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2004:103-14.
95. French AE, Soldin SJ, Soldin OP, Koren G. Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother 2003;37:815-8.
96. Gardiner SJ, Begg EJ. Breastfeeding during tacrolimus therapy. Obstet Gynecol 2006;107:453-5.
97. Bramham K, Chusney G, Lee J, Lightstone L, Nelson-Piercy C. Breastfeeding and tacrolimus: serial monitoring in breastfed and bottle-fed infants. Clin J Am Soc Nephrol 2013;8:563-7.
98. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255-8.
99. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009;43:613-6.
100. Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011;5:555-8.
101. Keeling S, Wolbink GJ. Measuring multiple etanercept levels in the breast milk of a nursing mother with rheumatoid arthritis [letter]. J Rheumatol 2010;37:1551.
102. Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology 2010;49:2225-7.
103. Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis 2009;68:1793-4.
104. Ben-Horin S, Yavzori M, Katz L, Picard O, Fudim E, Chowers Y, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010;8:475-6.
105. Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol 2007;58:138-49.
106. Broussard CS, Frey MT, Hernandez-Diaz S, Greene MF, Chambers CD, Sahin L, et al. Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention-convened meeting. Am J Obstet Gynecol 2014;211:208-14 e1.
107. US Food and Drug Administration. Pregnancy categories. URL: http://Chemm.nlm.nih.gov/pregnancycategories.htm.